Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) issued its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.16), Bloomberg Earnings reports. During the same quarter in the prior year, the company posted ($0.14) EPS.
Achillion Pharmaceuticals (ACHN) traded down 4.30% during midday trading on Friday, reaching $4.67. 1,489,155 shares of the company traded hands. The company’s market capitalization is $638.67 million. The stock’s 50 day moving average is $4.45 and its 200 day moving average is $4.16. Achillion Pharmaceuticals has a one year low of $3.15 and a one year high of $9.49.
ACHN has been the subject of several recent research reports. Robert W. Baird increased their target price on shares of Achillion Pharmaceuticals from $5.00 to $10.00 and gave the stock an “outperform” rating in a report on Monday, April 24th. Maxim Group cut their target price on shares of Achillion Pharmaceuticals from $8.00 to $5.00 and set a “buy” rating for the company in a research note on Tuesday, April 25th. Jefferies Group LLC reaffirmed a “hold” rating on shares of Achillion Pharmaceuticals in a research report on Wednesday, April 26th. Zacks Investment Research lowered shares of Achillion Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, May 10th. Finally, Leerink Swann raised shares of Achillion Pharmaceuticals from a “market perform” rating to an “outperform” rating and raised their price target for the stock from $4.00 to $6.00 in a research report on Thursday, May 18th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating to the company. Achillion Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $8.25.
COPYRIGHT VIOLATION NOTICE: “Achillion Pharmaceuticals, Inc. (ACHN) Announces Earnings Results” was first published by Rincon Hill News and is the property of of Rincon Hill News. If you are viewing this piece on another domain, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be accessed at https://rinconhillneighbors.org/2017/08/19/achillion-pharmaceuticals-inc-achn-releases-earnings-results-meets-expectations-updated.html.
Achillion Pharmaceuticals Company Profile
Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.
Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.